Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Pharmacotherapy ; 39(7): 734-740, 2019 07.
Artículo en Inglés | MEDLINE | ID: mdl-31148192

RESUMEN

INTRODUCTION: The management of pyogenic liver abscesses usually requires 4 weeks of antibiotic therapy. It is unknown if oral (PO) antibiotics are as effective as intravenous (IV) antibiotics for this indication. OBJECTIVES: To compare 30-, 60-, and 90-day readmission rates between patients with pyogenic liver abscesses receiving IV antibiotics for the duration of therapy and those who were transitioned to PO antibiotics after discharge from the hospital. METHODS: This retrospective study included patients with pyogenic liver abscesses who had undergone percutaneous drainage and received IV antibiotics while in the hospital. Patients were grouped based on receipt of either PO or IV antibiotics at discharge. RESULTS: The final cohort resulted in 99 patients, 48 in the PO group and 51 in the IV group. The most common organisms identified were Klebsiella sp, Escherichia coli, and Streptococcus sp. The most common antibiotic received at discharge in the IV group was ertapenem or ceftriaxone plus metronidazole. Patients in the PO group most commonly received levofloxacin plus metronidazole at discharge. Thirty-day readmission occurred more frequently in the PO group (PO 39.6% vs IV 17.6%, p=0.03). The most common reasons for readmission were complications related to abscess or antibiotic. Univariate logistic regression for readmission identified PO antibiotics at discharge as an independent predictor of readmission at 30 days (odds ratio [OR] 3.1), 60 days (OR 3.9), and 90 days (OR 3.1). CONCLUSION: Transition to PO antibiotics that consisted mostly of fluoroquinolones for patients with pyogenic liver abscesses was associated with a higher rate of 30-day readmission compared with patients treated with IV antibiotics that consisted mostly of ß-lactams.


Asunto(s)
Antibacterianos/administración & dosificación , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Grampositivas/tratamiento farmacológico , Absceso Piógeno Hepático/tratamiento farmacológico , Administración Intravenosa , Administración Oral , Antibacterianos/uso terapéutico , Estudios de Cohortes , Esquema de Medicación , Femenino , Infecciones por Bacterias Gramnegativas/epidemiología , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Grampositivas/epidemiología , Infecciones por Bacterias Grampositivas/microbiología , Humanos , Absceso Piógeno Hepático/epidemiología , Absceso Piógeno Hepático/microbiología , Masculino , Persona de Mediana Edad , Readmisión del Paciente/estadística & datos numéricos , Estudios Retrospectivos , Resultado del Tratamiento
2.
Genome Announc ; 6(18)2018 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-29724843

RESUMEN

We report here the draft genome sequence of Pseudomonas putida strain DRA525, isolated from mercury-contaminated soil. This strain shows resistance to mercury and multiple antibiotics, and its genome sequence contains several gene sets known to confer resistance to heavy metals enzymatically and through multidrug efflux pumps.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA